万邦德(002082) - 2020 Q3 - 季度财报

Financial Performance - Net profit attributable to shareholders decreased by 99.62% to CNY 206.58 million, down from CNY 53.83 million in the same period last year[8]. - Operating revenue for the reporting period was CNY 4.51 billion, representing a decline of 10.10% year-on-year[8]. - Basic earnings per share dropped to CNY 0.0003, a decrease of 99.66% from CNY 0.0871 in the same period last year[8]. - The net profit after deducting non-recurring gains and losses was CNY -17.90 million, a decrease of 133.75% compared to the previous year[8]. - The company reported a total comprehensive income of CNY -6,339,334.23 for Q3 2020, compared to CNY 60,384,614.17 in the previous year[43]. - Net profit for Q3 2020 was CNY -921,475.06, a significant decrease from CNY 69,351,891.43 in the previous year[42]. - The total profit for the period was ¥160,573,934.28, down from ¥259,151,275.29 in the previous period[49]. - The net cash flow from operating activities was negative at CNY -72.34 million, a decrease of 78.16% compared to the previous year[8]. - The company reported a tax expense of ¥35,681,400.79, compared to ¥48,209,527.72 in the previous period[49]. Assets and Liabilities - Total assets at the end of the reporting period reached approximately CNY 5.11 billion, a slight increase of 0.08% compared to the previous year[8]. - The company's total liabilities increased to CNY 2,418,498,354.69 from CNY 2,279,300,592.96, marking an increase of about 6.1%[34]. - The company's total assets amounted to CNY 5,113,578,472.93, showing a slight increase from CNY 5,109,471,140.05 at the end of 2019[32][35]. - The company's cash and cash equivalents decreased significantly to CNY 288,424,292.30 from CNY 781,780,267.60 at the end of 2019, representing a decline of approximately 63.1%[32]. - The company's total liabilities decreased to CNY 515,717,573.58 from CNY 574,293,312.77 year-on-year[38]. - The company's equity attributable to the owners of the parent company decreased to CNY 2,437,007,526.57 from CNY 2,537,656,949.99, a decline of approximately 3.9%[35]. - The total assets amounted to 5,109,471,140.05 CNY, with total liabilities at 2,279,300,592.96 CNY, resulting in total equity of 2,830,170,547.09 CNY[68]. Cash Flow - The net cash flow from operating activities was negative at -¥232,739,111.66, a 60.24% increase in outflow compared to -¥145,242,699.59 in the previous year[17]. - The company's cash flow from operating activities showed a negative trend, indicating potential challenges in operational efficiency[62]. - The net cash flow from operating activities was -236,702,097.49 CNY, compared to -105,652,077.14 CNY in the previous year, indicating a decline of approximately 124% year-over-year[62]. - The company recorded a decrease in cash and cash equivalents, ending the period with ¥281,360,667.82, down from ¥430,712,934.54 in the previous period[59]. - The company's investment activities resulted in a net cash outflow of -¥639,896,531.43, compared to -¥443,861,449.40 in the previous period, indicating increased investment expenditures[58]. Shareholder Information - The total number of shareholders at the end of the reporting period was 26,066, with the largest shareholder holding 31.46% of the shares[12]. - The company has made adjustments to its financial data due to business combinations under common control[8]. Investment and Financing Activities - The company reported non-operating income of CNY 24.29 million, primarily from government subsidies and non-monetary asset exchanges[10]. - The company plans to sell 100% equity of its wholly-owned subsidiary Dongliang Aluminum Co., Ltd. and 51% equity of its holding subsidiary Huzhou Jiacheng Metal Coating Co., Ltd.[18]. - The company completed a major asset restructuring by issuing 380,222,829 shares to acquire 100% equity of Wanbang Pharmaceutical Group Co., Ltd. on March 5, 2020[19]. - The company received cash inflows from financing activities totaling ¥1,263,855,414.73, an increase from ¥1,083,909,409.59 in the previous period, indicating improved financing efforts[59]. Research and Development - Research and development expenses for Q3 2020 were CNY 57,738,767.61, compared to CNY 45,179,448.44 in the same period last year[41]. - Research and development expenses were ¥127,291,919.15, slightly up from ¥120,760,847.89 in the previous period[49].